3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
23
Breast Neoplasms
16
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Ovarian Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Endometrial Neoplasms
1
Dementia
1
Cognitive Dysfunction
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
enzalutamide
4
Docetaxel
3
abiraterone
2
Prednisone
2
Abiraterone Acetate
2
relugolix
1
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
Gonadotropin-Releasing Hormone
×
1 year
×
Clear all
NCT06531499
2025-12-31
RADIODOSE
Novartis
Phase 1
Recruiting
106 enrolled